炎症性腸疾患治療市場の2030年までの予測- タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別の世界分析

Stratistics MRCによると、世界の炎症性腸疾患治療市場は2023年に214億7,000万米ドルを占め、予測期間中のCAGRは5.6％で成長し、2030年には314億4,000万米ドルに達すると予測されています。

「炎症性腸疾患」（IBD）という用語は、潰瘍性大腸炎とクローン病という、消化管が慢性的に炎症を起こす2つの疾患を指します。消化器系は炎症によって長期にわたって損傷を受ける。過敏性腸症候群の治療の目標は、症状や徴候の原因である炎症を抑えることです。最良のシナリオでは、症状の緩和、長期的な寛解、合併症リスクの低下につながる可能性があります。IBDの治療には通常、薬物療法か手術療法が用いられます。

ClinicalTrials.gov.によると、IBDに関連する臨床試験（薬物開発、観察研究、その他を含む）2,784件のうち、現在米国だけで965件の臨床試験が実施されています。

市場力学：

有病率の増加により、治療を受ける患者数が増加

潰瘍性大腸炎とクローン病の有病率の上昇には、遺伝的素因、環境的誘因、免疫系の障害など多くの要因が関与しています。潰瘍性大腸炎やクローン病に罹患する人の大半は、家族歴があります。これらの病気の症状、診断、治療法について一般の人々に啓蒙することで、多くの政府機関がこれらの病気に対する一般の人々の意識を高めています。したがって、さまざまな治療法に対する消費者の意識の高まりと新興国での疾病診断率の上昇が市場拡大を後押しすると予測されます。

高コスト

発展途上国では、炎症性腸疾患に関する知識が不足しているため、治療を受ける人の数が減少しています。さらに、薬剤やその他の費用を含む高額な治療費が、炎症性腸疾患治療の患者への使用を制限することも予想されます。さらに、潰瘍性大腸炎やクローン病の治療に生物学的製剤が使用される頻度が高まっているが、生物学的製剤による治療費の高さが市場の拡大を抑制しています。

パイプライン分子の強力なポートフォリオによる製品上市の増加

炎症性腸疾患治療市場の成長を牽引する要因としては、クローン病や潰瘍性大腸炎の有病率の上昇、世界規模での認知度の向上などが挙げられます。その結果、多くの重要な業界企業が研究開発に注力し、IBD治療の新たな有望候補を模索しています。

新薬の限られたパイプラインと技術的課題

IBDの治療薬として開発されている新薬の数は少なく、そのほとんどが類似した作用機序に焦点を当てています。その結果、製薬業界は医薬品の差別化が難しくなり、価格が上昇する可能性があります。IBD市場には、臨床試験、添付文書、安全性監視に関する法律など、多くの法律が関係しています。製薬企業にとって、これらの規則を遵守することは時間と費用のかかることです。

COVID-19の影響：

COVID-19の影響により、炎症性腸疾患の治療市場は予測期間中、より緩やかに拡大しました。世界各国における診断施設の閉鎖、渡航制限、封鎖は、この疾患の治療速度の遅れに寄与している原因の一部です。2020年に発生した収益は、2019年に比べて大幅に減少しました。

クローン病セグメントは予測期間中最大となる見込み

クローン病セグメントは予測期間中最大のシェアを占めると予想されます。クローン病の罹患率の上昇と、国際的にクローン病の治療を受けている人の数は、いずれもこの市場の拡大を促進していると評価されています。例えば、Deutsches Arztblattによると、ドイツでは人口10万人当たり100～200人のクローン病患者がいるといわれています。

予測期間中にCAGRが最も高くなると予想されるのは注射剤セグメントです。

潰瘍性大腸炎やクローン病の治療における生物学的製剤の使用量の増加だけでなく、生物学的製剤の製品承認の増加により、注射剤分野は予測期間中に最も高いCAGRを示すと予想されます。例えば、アッヴィ社は2021年2月、若年性患者における中等度から重度の活動性潰瘍性大腸炎の治療薬としてヒュミラをFDAが承認したと発表しました。ヒュミラは皮下注射によって投与されます。このように、注射剤分野の拡大は、IBD治療のための生物製剤に対する需要の高まりに支えられています。

最もシェアの高い地域

北米が炎症性腸疾患治療の世界市場を席巻したのは、強力な市場企業が多数存在し、彼らが戦略的イニシアチブを数多く実施した結果です。さらに、同地域の償還慣行の改善、高い治療率、革新的な治療法の処方の増加が、同地域の拡大を後押ししています。同地域の拡大は、革新的な治療法を発見するための継続的な努力や政府の支援策によっても促進されると予測されます。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域が最も高い成長を遂げると予測されます。今後数年間の市場拡大を促進する主な理由としては、人口の高齢化、炎症性疾患の市場開発の可能性の高さ、炎症性腸疾患の有病率の増加、同地域におけるより良いヘルスケア政策などが挙げられます。さらに、同地域の主要企業による投資の増加、バイオシミラーや生物製剤の受け入れ拡大が、近い将来の市場拡大を後押しすると予想されます。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下のいずれかの無料カスタマイズオプションをご提供いたします：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• エグゼクティブサマリー
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 一次調査情報源
  • 二次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 炎症性腸疾患治療の世界市場：タイプ別

• 潰瘍性大腸炎
• クローン病

第6章 炎症性腸疾患治療の世界市場：薬剤クラス別

• JAK阻害剤
• 抗インテグリン薬
• IL阻害剤
• TNF阻害薬
• 副腎皮質ステロイド
• アミノサリチル酸塩
• その他の薬剤クラス別

第7章 炎症性腸疾患治療の世界市場：投与経路別

• 注射剤
• 経口剤

第8章 炎症性腸疾患治療の世界市場：流通チャネル別

• オンライン薬局
• 小売薬局
• 病院薬局

第9章 炎症性腸疾患治療の世界市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、提携、合弁事業
• 買収と合併
• 新製品の上市
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• Allergan plc.
• Janssen Biotech
• Celltrion Inc.
• Pfizer Inc
• Merck & co., inc
• Bristol-myers squibb company
• Bausch health companies inc
• Takeda Pharmaceutical Company Limited
• Novartis AG
• UCB S.A.
• Amgen Inc
• Johnson & Johnson Services, Inc
• Biogen
• AbbVie Inc.,

List of Tables

• Table 1 Global Inflammatory Bowel Disease Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 4 Global Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 5 Global Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 6 Global Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 7 Global Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 8 Global Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 9 Global Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 10 Global Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 11 Global Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 12 Global Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 13 Global Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 14 Global Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 15 Global Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 16 Global Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 17 Global Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 18 Global Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 19 Global Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 20 North America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 22 North America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 23 North America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 24 North America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 25 North America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 26 North America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 27 North America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 28 North America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 29 North America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 30 North America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 31 North America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 32 North America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 33 North America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 34 North America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 35 North America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 36 North America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 37 North America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 38 North America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 39 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 41 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 42 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 43 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 44 Europe Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 45 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 46 Europe Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 47 Europe Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 48 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 49 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 50 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 51 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 52 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 53 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 54 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 55 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 56 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 57 Europe Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 58 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 60 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 61 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 62 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 63 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 64 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 65 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 66 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 67 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 68 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 69 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 70 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 71 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 72 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 73 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 74 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 75 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 76 Asia Pacific Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 77 South America Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 79 South America Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 80 South America Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 81 South America Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 82 South America Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 83 South America Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 84 South America Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 85 South America Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 86 South America Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 87 South America Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 88 South America Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 89 South America Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 90 South America Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 91 South America Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 92 South America Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 93 South America Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 94 South America Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 95 South America Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
• Table 96 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 98 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Ulcerative Colitis (2021-2030) ($MN)
• Table 99 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Crohn's Disease (2021-2030) ($MN)
• Table 100 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
• Table 101 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By JAK inhibitors (2021-2030) ($MN)
• Table 102 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Anti-integrin (2021-2030) ($MN)
• Table 103 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By IL inhibitors (2021-2030) ($MN)
• Table 104 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By TNF inhibitors (2021-2030) ($MN)
• Table 105 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
• Table 106 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Aminosalicylates (2021-2030) ($MN)
• Table 107 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Other Drug Class (2021-2030) ($MN)
• Table 108 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
• Table 109 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Injectable (2021-2030) ($MN)
• Table 110 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Oral (2021-2030) ($MN)
• Table 111 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 112 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Online Pharmacy (2021-2030) ($MN)
• Table 113 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
• Table 114 Middle East & Africa Inflammatory Bowel Disease Treatment Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)

According to Stratistics MRC, the Global Inflammatory Bowel Disease Treatment Market is accounted for $21.47 billion in 2023 and is expected to reach $31.44 billion by 2030 growing at a CAGR of 5.6% during the forecast period. The term "inflammatory bowel disease" (IBD) is used to describe ulcerative colitis and Crohn's disease, two conditions in which the GI tract is chronically inflamed. The digestive system becomes damaged over time by inflammation. The goal of treating irritable bowel syndrome is to reduce the inflammation that is the source of your signs and symptoms. In the best-case scenario, this might lead to symptom relief, a long-term remission, and lowered complications risks. For the treatment of IBD, drugs or surgery are usually employed.

According to ClinicalTrials.gov., there are currently 965 clinical trials being undertaken in the United States alone out of the 2,784 clinical trials (including medication development, observational studies, and others) connected to IBD.

Market Dynamics:

Driver:

Increasing prevalence of disease is presenting a large patient pool undergoing treatment

Many factors, including genetic predisposition, environmental triggers, and immune system disturbances, are responsible for the rising prevalence of ulcerative colitis and Crohn's disease. The majority of individuals who have ulcerative colitis or Crohn's disease have a family history of the condition. By educating the public about these diseases' symptoms, diagnoses, and treatments, a number of government agencies are raising public awareness of these illnesses. Therefore, it is projected that growing consumer awareness of various treatment alternatives and rising disease diagnosis rates in developing nations will boost market expansion.

Restraint:

High cost

In underdeveloped nations, there is a lack of knowledge regarding inflammatory bowel disease, which lowers the number of individuals receiving treatment. Additionally, it is anticipated that high treatment costs, including those associated with drugs and other expenses, may restrict the use of an inflammatory bowel disease treatment among patients. Additionally, biologics are being used more frequently to treat ulcerative colitis and Crohn's disease, but the market expansion is being constrained by the high costs of biologic treatment.

Opportunity:

Strong portfolio of pipeline molecules to increase product launches

Some of the reasons driving the growth of the inflammatory bowel disease treatment market include the rising prevalence of Crohn's disease and ulcerative colitis, as well as increased awareness of the condition on a global scale. As a result, a number of important industry firms are concentrating on R&D and looking into new prospective candidates for the treatment of IBD.

Threat:

Limited pipeline of new drugs and technical challenges

The number of new medications being developed to treat IBD is rather small, and most of them focus on similar mechanisms of action. The pharmaceutical industry may find it harder to differentiate its medicines as a result, which may put pressure on prices. A number of laws, including those governing clinical trials, labeling, and safety monitoring, pertain to the IBD market. For pharmaceutical companies, complying with these rules can be time- and money-consuming.

COVID-19 Impact:

The market for treating inflammatory bowel disease expanded more slowly during the predicted period as a result of COVID-19's effects. The closure of diagnostic facilities, travel restrictions, and lockdowns in numerous nations worldwide are a few of the causes contributing to the disease's delayed rate of treatment. The revenue generated in 2020 was significantly lower than it was in 2019.

The crohn's disease segment is expected to be the largest during the forecast period

The Crohn's disease segment is expected to hold the largest share during the forecast period. The rising incidence of Crohn's disease and the number of people undergoing treatment for it internationally are both credited with driving the expansion of this market. For instance, according to the Deutsches Arztblatt, there are 100 to 200 cases of Crohn's disease per 100,000 people in Germany.

The injectables segment is expected to have the highest CAGR during the forecast period

Due to rising product approvals for biologics as well as rising biologic usage for the treatment of ulcerative colitis and Crohn's disease, the injectables sector is anticipated to have the highest CAGR over the projection period. For instance, AbbVie Inc. announced in February 2021 that the FDA had approved HUMIRA for the treatment of moderate to severe active ulcerative colitis in juvenile patients. Through subcutaneous injections, HUMIRA is administered. Thus, the expansion of the injectables sector is supported by the rising demand for biologics for the treatment of IBD.

Region with largest share:

North America dominated the global market for the treatment of inflammatory bowel disease as a result of the existence of numerous powerful market players and the numerous strategic initiatives they carried out there. Additionally, the region's improved reimbursement practices, high treatment rates, and rising prescription of innovative treatments are aiding regional expansion. The region's expansion is also predicted to be fueled by continuous efforts to discover innovative therapies and supportive government initiatives.

Region with highest CAGR:

Over the forecast period, Asia-Pacific is expected to experience the highest growth. Some of the key reasons driving market expansion in the upcoming years include an aging population, a high chance of developing inflammatory diseases, an increase in the prevalence of inflammatory bowel diseases, and better healthcare policies in the area. Additionally, increased investments by top players in the region and the increasing acceptance of biosimilars and biologics are anticipated to fuel market expansion in the near future.

Key players in the market:

Some of the key players in Inflammatory Bowel Disease Treatment market include: Allergan plc., Janssen Biotech, Celltrion Inc., Pfizer Inc, Merck & co., inc, Bristol-myers squibb company, Bausch health companies inc, Takeda Pharmaceutical Company Limited, Novartis AG, UCB S.A., Amgen Inc, Johnson & Johnson Services, Inc, Biogen and AbbVie Inc.

Key Developments:

In October 2021, Bristol-Myers Squibb Company announced the approval of Zeposia (ozanimod) by the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).

In February 2021, the European Commission (EC) granted marketing authorization to CELLTRION INC.'s Yuflyma biosimilar used to treat adult and pediatric Crohn's disease and ulcerative colitis.

Types Covered:

• Ulcerative Colitis
• Crohn's Disease

Drug Class Covered:

• JAK inhibitors
• Anti-integrin
• IL inhibitors
• TNF inhibitors
• Corticosteroids
• Aminosalicylates
• Other Drug Class

Route of Administrations Covered:

• Injectable
• Oral

Distribution Channels Covered:

• Online Pharmacy
• Retail Pharmacy
• Hospital Pharmacy

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Inflammatory Bowel Disease Treatment Market, By Type

• 5.1 Introduction
• 5.2 Ulcerative Colitis
• 5.3 Crohn's Disease

6 Global Inflammatory Bowel Disease Treatment Market, By Drug Class

• 6.1 Introduction
• 6.2 JAK inhibitors
• 6.3 Anti-integrin
• 6.4 IL inhibitors
• 6.5 TNF inhibitors
• 6.6 Corticosteroids
• 6.7 Aminosalicylates
• 6.8 Other Drug Class

7 Global Inflammatory Bowel Disease Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Injectable
• 7.3 Oral

8 Global Inflammatory Bowel Disease Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Online Pharmacy
• 8.3 Retail Pharmacy
• 8.4 Hospital Pharmacy

9 Global Inflammatory Bowel Disease Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Allergan plc.
• 11.2 Janssen Biotech
• 11.3 Celltrion Inc.
• 11.4 Pfizer Inc
• 11.5 Merck & co., inc
• 11.6 Bristol-myers squibb company
• 11.7 Bausch health companies inc
• 11.8 Takeda Pharmaceutical Company Limited
• 11.9 Novartis AG
• 11.10 UCB S.A.
• 11.11 Amgen Inc
• 11.12 Johnson & Johnson Services, Inc
• 11.13 Biogen
• 11.14 AbbVie Inc.,